Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1992-9-21
|
pubmed:abstractText |
Evoked potentials were recorded in rat cerebral cortical slices. The amplitude of the evoked potential was reduced by perfusion with hypoxic (0-25%) or low glucose (0-5 mM) media in a concentration-dependent manner, and the evoked potentials disappeared under severe conditions (below 15% O2, below 3 mM glucose). We investigated the protective effects of oxiracetam on the decrease in evoked potentials under hypoxic (15% O2) and low glucose (3 mM glucose) conditions. Drugs were perfused from 45 min before hypoxic or low glucose perfusion to the end of the experiment. Oxiracetam (10(-6)-10(-5) M) dose-dependently minimized the amplitude reduction of evoked potentials and prolonged their disappearance time. At a concentration of 10(-5) M, oxiracetam protected against the disappearance of evoked potential in 5 of the 6 samples under hypoxic conditions and in all 6 samples under low glucose conditions. Indeloxazine (5 x 10(-6)-10(-5) M) and bifemelane (5 x 10(-6)-10(-5) M) prevented the reduction of the amplitude of evoked potentials under low glucose conditions. However, these drugs had no effect at a concentration of 10(-6) M. These data indicate that oxiracetam has a protective effect against neuronal dysfunction and that this effect develops at a lower concentration than those of indeloxazine and bifemelane.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzhydryl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Morpholines,
http://linkedlifedata.com/resource/pubmed/chemical/Psychotropic Drugs,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidines,
http://linkedlifedata.com/resource/pubmed/chemical/bifemelane,
http://linkedlifedata.com/resource/pubmed/chemical/indeloxazine,
http://linkedlifedata.com/resource/pubmed/chemical/oxiracetam
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0015-5691
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
99
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
123-33
|
pubmed:dateRevised |
2011-7-27
|
pubmed:meshHeading |
pubmed-meshheading:1505853-Animals,
pubmed-meshheading:1505853-Benzhydryl Compounds,
pubmed-meshheading:1505853-Cerebral Cortex,
pubmed-meshheading:1505853-Evoked Potentials,
pubmed-meshheading:1505853-Glucose,
pubmed-meshheading:1505853-Hypoxia, Brain,
pubmed-meshheading:1505853-Male,
pubmed-meshheading:1505853-Morpholines,
pubmed-meshheading:1505853-Perfusion,
pubmed-meshheading:1505853-Psychotropic Drugs,
pubmed-meshheading:1505853-Pyrrolidines,
pubmed-meshheading:1505853-Rats,
pubmed-meshheading:1505853-Rats, Inbred Strains
|
pubmed:year |
1992
|
pubmed:articleTitle |
[Effects of oxiracetam on the decrease in population spikes in hypoxic and low glucose media].
|
pubmed:affiliation |
Research Laboratories TOYO JOZO Co., Ltd., Shizuoka, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro,
English Abstract
|